Search

Your search keyword '"Ceribelli, Angela"' showing total 8 results
Start Over Author "Ceribelli, Angela" Topic biomarkers
8 results on '"Ceribelli, Angela"'

4. Anti-RNA polymerase III antibodies: A marker of systemic sclerosis with rapid onset and skin thickening progression

Author

Ilaria, Cavazzana, Angela, Ceribelli, Ceribelli, Angela, Paolo, Airo', Airo', Paolo, Stefania, Zingarelli, Zingarelli, Stefania, Angela, Tincani, Tincani, Angela, Franco, Franceschini, and Franceschini, Franco

Subjects
Male, Pathology, medicine.medical_specialty, Anti-nuclear antibody, Immunology, Rapid systemic sclerosis onset, Systemic Sclerosis, Disease, Scleroderma, RNA polymerase III, Antibody Specificity, medicine, Humans, Immunology and Allergy, skin and connective tissue diseases, Autoantibodies, Skin, Scleroderma, Systemic, integumentary system, biology, Anti-RNA polymerase III, Skin thickening, business.industry, Systemic, Autoantibody, RNA Polymerase III, Middle Aged, Anti-nuclear antibodies, medicine.disease, Raynaud's phenomenon, Skin thickening progression, Rapid onset, Disease Progression, biology.protein, Female, Biomarkers, Antibody, business
Abstract

Anti-RNA polymerase III antibodies (ARA) are a specific marker for Systemic Sclerosis (SSc), associated to severe disease with major organ and diffuse cutaneous involvement. In our series, ARA were found in 19 of 216 sera, in 15 cases as isolated antibodies' specificity, with a statistically negative association with other SSc-specific autoantibodies (p: 0.00003). The prevalence of ARA among 73 anticentromere and anti-topoisomerase I (topo I) negative sera, was 20.5%. Patients with isolated ARA had more rapid disease onset, defined as the interval from the appearance of Raynaud's phenomenon to the first symptom other than Raynaud's, than patients with isolated anti-topo I antibodies (median: 2 months vs 13 months; p: 0.0013). A rapid onset of SSc (within 6 months from Raynaud's phenomenon onset) was found in all patients with isolated ARA and only in 34% of those with anti-topo I (p

Published
2009

5. MicroRNAs in rheumatoid arthritis

Author

Ceribelli, Angela, Nahid, Md A., Satoh, Minoru, and Chan, Edward K.L.

Subjects
*MICRORNA, *RHEUMATOID arthritis, *AUTOANTIBODIES, *BIOMARKERS, *GENE expression, *INTERLEUKINS
Abstract

Abstract: Rheumatoid arthritis (RA) is a chronic and severe autoimmune disease that affects joint tissues, bone, and cartilage. However, the pathogenesis of RA is still unclear. Autoantibodies such as rheumatoid factor and anti-cyclic citrullinated peptide are useful tools for early diagnosis, monitoring disease activity, and predicting prognosis. Recently, many groups have focused their attention on the role of microRNAs in the pathogenesis of RA, as well as a potential biomarker to monitor RA. In fact, the expression of some microRNAs, such as miR-146a, is upregulated in different cell types and tissues in RA patients. MicroRNAs in RA could also be considered as possible future targets for new therapeutic approaches. [Copyright &y& Elsevier]

Published
2011
Full Text
View/download PDF

6. Autoantibodies to survival of motor neuron complex in patients with polymyositis: Immunoprecipitation of D, E, F, and G proteins without other components of small nuclear ribonucleoproteins.

Author

Satoh, Minoru, Chan, Jason Y. F., Ross, Steven J., Ceribelli, Angela, Cavazzana, Ilaria, Franceschini, Franco, Li, Yi, Reeves, Westley H., Sobel, Eric S., and Chan, Edward K. L.

Subjects
AUTOIMMUNE disease diagnosis, DIAGNOSIS of muscle diseases, ANALYSIS of variance, AUTOANTIBODIES, BIOMARKERS, REPORTING of diseases, FLUORESCENT antibody technique, MEDICAL cooperation, RESEARCH, RESEARCH funding, WESTERN immunoblotting, EQUIPMENT & supplies
Abstract

Objective Autoantibodies in the systemic rheumatic diseases are clinically useful biomarkers of the diagnosis or of certain clinical characteristics. An unusual pattern of immunoprecipitation, in which the D, E, F, and G proteins of small nuclear RNPs (snRNP) but without other components of the snRNP, was noticed at the autoantibody screening. The purpose of this study was to examine the target antigens and clinical manifestations associated with this specificity. Methods Autoantibodies in sera from 1,966 American patients (including 434 with systemic lupus erythematosus, 121 with scleroderma, 86 with polymyositis/dermatomyositis [PM/DM]) and 248 Italian patients with autoimmune diseases were screened by immunoprecipitation of [ABSTRACT FROM AUTHOR]

Published
2011
Full Text
View/download PDF

7. Humoral Response Against LL‐37 in Psoriatic Disease: Comment on the Article by Yuan et al.

Author

De Santis, Maria, Isailovic, Natasa, Generali, Elena, Ceribelli, Angela, Altamore, Lorenzo, Real‐Fernandez, Feliciana, Papini, Anna Maria, Rovero, Paolo, Sabatino, Giuseppina, and Selmi, Carlo

Subjects
AUTOANTIBODIES, B cells, BIOMARKERS, ENZYME-linked immunosorbent assay, FLOW cytometry, GENE expression, IMMUNOGLOBULINS, INTERFERONS, PSORIATIC arthritis, T cells, HLA-B27 antigen, ANTIBODY formation, MONONUCLEAR leukocytes
Published
2019
Full Text
View/download PDF

8. The clinical phenotype of Systemic Sclerosis patients with anti-PM/Scl antibodies: results from the EUSTAR cohort

Author

Vanessa Smith, Ellen De Langhe, Elisabetta Zanatta, Jorge Rojas-Serrano, Christopher P. Denton, Roger Hesselstrand, Lorenzo Cavagna, Franco Franceschini, Montserrat-Ixchel Gonzalez-Perez, Angela Ceribelli, Konstantinos Triantafyllias, Marie-Elise Truchetet, Federica Furini, Giacomo De Luca, Alessio Furloni, Francesco Del Galdo, Yannick Allanore, Ilaria Cavazzana, Hadi Poormoghim, Corrado Campochiaro, G. Abignano, M. G. Lazzaroni, Francesca Ingegnoli, Paolo Airò, Silvia Bellando-Randone, Emiliano Marasco, Eugenia Bertoldo, Enrico Colombo, Eric Hachulla, S. Zingarelli, Oliver Distler, Jeska DeVries-Bouwstra, Simone Barsotti, Lazzaroni, Maria-Grazia, Marasco, Emiliano, Campochiaro, Corrado, DeVries-Bouwstra, Jeska, Gonzalez-Perez, Montserrat-Ixchel, Rojas-Serrano, Jorge, Hachulla, Eric, Zanatta, Elisabetta, Barsotti, Simone, Furini, Federica, Triantafyllias, Konstantino, Abignano, Giuseppina, Truchetet, Marie-Elise, De Luca, Giacomo, De Langhe, Ellen, Hesselstrand, Roger, Ingegnoli, Francesca, Bertoldo, Eugenia, Smith, Vanessa, Bellando-Randone, Silvia, Poormoghim, Hadi, Colombo, Enrico, Ceribelli, Angela, Furloni, Alessio, Zingarelli, Stefania, Cavazzana, Ilaria, Franceschini, Franco, Del Galdo, Francesco, Denton, Christopher P, Cavagna, Lorenzo, Distler, Oliver, Allanore, Yannick, and Airò, Paolo

Subjects
Adult, Male, Myositis and muscle disease, medicine.medical_specialty, Scleroderma Renal Crisis, Laboratory Diagnosis, Systemic scleroderma, behavioral disciplines and activities, Gastroenterology, Scleroderma, Rheumatology, Calcinosis, Internal medicine, Scleroderma and related disorders, Myositis and muscle disease, Autoantigens and Autoantibodies, Biomarkers, Laboratory Diagnosis, medicine, Humans, Pharmacology (medical), autoantigens and autoantibodies, biomarkers, laboratory diagnosis, myositis and muscle disease, scleroderma and related disorders, Autoantibodies, Europe, Exoribonucleases, Exosome Multienzyme Ribonuclease Complex, Female, Middle Aged, Phenotype, Retrospective Studies, Scleroderma, Systemic, Registries, skin and connective tissue diseases, integumentary system, business.industry, Systemic, Autoantigens and Autoantibodies, Autoantibody, Interstitial lung disease, Cancer, Dermatomyositis, medicine.disease, Scleroderma and related disorders, Cohort, business, Biomarkers
Abstract

Objective To evaluate clinical associations of anti-PM/Scl antibodies in patients with SSc in a multicentre international cohort, with particular focus on unresolved issues, including scleroderma renal crisis (RC), malignancies, and functional outcome of interstitial lung disease (ILD). Methods (1) Analysis of SSc patients from the EUSTAR database: 144 anti-PM/Scl+ without SSc-specific autoantibodies were compared with 7202 anti-PM/Scl−, and then to 155 anti-Pm/Scl+ with SSc-specific antibodies. (2) Case–control study: additional data were collected for 165 anti-PM/Scl+ SSc patients (85 from the EUSTAR registry) and compared with 257 anti-PM/Scl− SSc controls, matched for sex, cutaneous subset, disease duration and age at SSc onset. Results Patients with isolated anti-PM/Scl+, as compared with anti-Pm/Scl−, had higher frequency of muscle involvement, ILD, calcinosis and cutaneous signs of DM, but similar frequency of SRC and malignancies (either synchronous with SSc onset or not). The presence of muscle involvement was associated with a more severe disease phenotype. Although very frequent, ILD had a better functional outcome in cases than in controls. In patients with both anti-PM/Scl and SSc-specific antibodies, a higher frequency of typical SSc features than in those with isolated anti-PM/Scl was observed. Conclusion The analysis of the largest series of anti-PM/Scl+ SSc patients so far reported helps to delineate a specific clinical subset with muscle involvement, cutaneous DM, calcinosis and ILD characterized by a good functional outcome. SRC and malignancies do not seem to be part of this syndrome.

Catalog

Books, media, physical & digital resources
See catalog results